Bosma Arhinia Microphthalmia Syndrome (BAMS)

Bosma arhinia microphthalmia syndrome (BAMS) is a very rare, genetic condition present from birth. The main features are: an absent or very under-developed nose (arhinia), small eyes (microphthalmia), a poor or absent sense of smell (anosmia), and problems with puberty due to low signals from the brain to the ovaries or testes (hypogonadotropic hypogonadism). Most cases happen sporadically (by chance) because of a new change (a de novo variant) in a gene called SMCHD1. Inheritance is autosomal dominant, but almost all reported patients have new, not inherited, variants. Intelligence is often normal, though associated findings can vary. PubMed+3PubMed+3MedlinePlus+3

Bosma arhinia microphthalmia syndrome (BAMS) is a very rare genetic condition. Children are born with little or no external nose (arhinia) and with very small eyes or eye under-development (microphthalmia). Many also have poor or absent sense of smell and taste, and delayed or absent puberty due to hypogonadotropic hypogonadism (the brain does not send enough signals to the sex glands). BAMS is strongly linked to changes (variants) in a gene called SMCHD1, which is important in early facial and nasal development. Because the nose and nasal passages help newborns breathe while feeding, babies with complete arhinia may have breathing and feeding trouble right after birth and need urgent airway support. Lifelong care usually involves ENT/craniofacial surgery teams, ophthalmology/low-vision services, endocrinology for puberty and fertility support, speech-language therapy, dentistry/orthodontics, and mental-health support. PMC+4MedlinePlus+4Orpha+4

SMCHD1 helps switch genes off at the right time during early development (it is an epigenetic silencer). Certain changes in SMCHD1 disturb facial, nasal, and reproductive development, leading to the BAMS features. (Different changes in the same gene can also cause a muscle condition called FSHD2, which teaches us that the exact mutation and its effect on SMCHD1’s function matters.) PMC+1

Other names

• BAM syndrome or BAMS – common short names. National Organization for Rare Disorders

• Congenital arhinia with microphthalmia – descriptive term highlighting nose and eye findings. PMC

• Hyposmia-nasal and ocular hypoplasia with hypogonadotropic hypogonadism – descriptive label used in rare-disease listings. Orpha

Types

Because this is rare, there is no single official “type” system. In practice, clinicians often describe BAMS along these lines:

1. Complete arhinia: the external nose and internal nasal passages are nearly or completely absent. This form causes the most breathing and feeding problems in newborns. PMC+1

2. Partial arhinia / severe nasal hypoplasia: parts of the nose or nasal cavities exist but are very small or closed (e.g., choanal atresia, where the back of the nose is blocked). Symptoms may be a bit milder but still significant. PubMed

3. Isolated arhinia vs. syndromic (BAMS): some people have arhinia without eye or hormonal problems (isolated arhinia); others have the full BAMS picture (nose, eye, smell, and puberty issues). Both can be linked to SMCHD1 changes. PubMed

4. Genotype-informed descriptions: many BAMS variants cluster in exons 3–13 of SMCHD1 (the extended ATPase/transducer domain). This region helps SMCHD1 dimerize and work properly. PMC

Causes

Established genetic cause

1. Pathogenic variants in SMCHD1 (the key cause): a single, harmful change in one SMCHD1 copy is enough to cause BAMS. Most are de novo (new in the child). PubMed+1

2. Missense variants in SMCHD1’s ATPase/transducer domain: many BAMS changes sit in early exons (3–13), altering energy-handling and protein pairing. This likely derails normal facial and olfactory development. PMC

3. Autosomal-dominant inheritance with variable expressivity: rarely, the variant can be inherited; the look of the condition can differ even within families. National Organization for Rare Disorders

Mechanism-level (how it likely happens)
These are mechanisms—not different “external” causes—and they help explain why SMCHD1 problems lead to BAMS:

4. Epigenetic dysregulation: SMCHD1 normally silences specific genes during early embryo development. Faults can let the wrong genes stay “on” or turn “off” at the wrong times. PMC

5. Failure of nasal placode induction: the nasal/olfactory placodes are early facial structures. If gene programs here are mis-timed, the nose and nasal passages may not form. PubMed

6. Abnormal olfactory bulb development: under-developed smell centers are often seen, tying smell loss to brain structure differences. PubMed

7. Disrupted craniofacial patterning signals: SMCHD1 errors likely disturb the gene networks that shape midline face structures (nose, palate). PubMed

8. Perturbed neural crest cell behavior: neural crest cells help build parts of the nose and face; dysregulation can alter their migration and fate. (Mechanistic inference from craniofacial biology in BAMS papers.) PubMed

9. Dosage-sensitive effect on development: small differences in SMCHD1 function can produce big effects in the embryo, which may explain variable severity. PMC

Context and associations

10. Overlap with isolated arhinia: some SMCHD1 mutations cause arhinia alone; BAMS adds eye and hormonal features. PubMed

11. Opposing functional effects vs FSHD2 mutations: some SMCHD1 changes that cause muscle disease act differently from BAMS changes, showing function-specific consequences. PMC

12. Mosaicism (possible): if the variant is present in only some cells, features may be patchy or milder (reported in rare genetic disorders generally; occasionally considered in BAMS workups). (Inference; counseling practice cites mosaicism as a possibility in de novo disorders.) National Organization for Rare Disorders

13. Chromatin organization defects: SMCHD1 helps organize DNA loops; faults can broadly affect gene neighborhoods important for facial and pituitary development. PMC

14. Disrupted GnRH neuron development: smell and puberty pathways are linked during development; mis-patterning can impair GnRH neuron formation/migration → low puberty signaling. PubMed

15. Choanal atresia as a downstream effect: improper formation of posterior nasal passages can accompany arhinia. PubMed

16. Palatal malformations (cleft, high-arched palate) as part of the same midline patterning error. PubMed

17. Abnormal pituitary–hypothalamic signaling: central hormone control can be affected, leading to hypogonadotropic hypogonadism. PubMed

18. Reduced or absent olfactory epithelium: no proper smell lining → anosmia/hyposmia. PubMed

19. Airway compromise in newborns: lack of nasal passages impairs normal neonatal breathing (newborns are preferential nasal breathers). PMC

20. Feeding difficulties due to craniofacial structure: poor coordination of suck-swallow-breathe when no nasal airflow is available. PMC

Note: Environmental or pregnancy-related external causes for BAMS are not established. The evidence strongly points to SMCHD1 genetic variants as the driver. PubMed+1

Symptoms and signs

1. Arhinia (absent nose): the nose and nasal passages are missing or very small from birth. This is the hallmark sign. PMC

2. Severe nasal hypoplasia: if some structures exist, they are very under-developed and may not support normal breathing. PubMed

3. Choanal atresia or stenosis: the back of the nasal cavity is blocked or narrow, worsening breathing problems. PubMed

4. Microphthalmia: one or both eyes are abnormally small; vision can range from normal to impaired. PMC

5. Ocular anomalies (e.g., coloboma): gaps in eye structures can affect the iris, retina, or optic nerve. PMC

6. Anosmia or hyposmia: smell is absent or reduced because olfactory tissue and bulbs are abnormal. PubMed

7. Hypogonadotropic hypogonadism: low GnRH/LH/FSH signals from the brain delay or prevent puberty; fertility may be affected. PubMed

8. Cryptorchidism (in males): one or both testes don’t descend into the scrotum. PubMed

9. Palatal abnormalities: cleft palate or a very high arch can affect feeding and speech. PubMed

10. Feeding difficulties in infancy: without nasal airflow, suck-swallow-breathe coordination is hard; weight gain may lag. PMC

11. Breathing distress in newborns: babies prefer to breathe through the nose; arhinia can cause cyanosis or labored breathing. PMC

12. Normal intelligence in many cases: brain structure is often normal, though smell centers may be small. PMC

13. Abnormal or absent nasal bones on exam or imaging. malacards.org

14. Hyposmia with taste changes (taste depends on smell), sometimes described historically as “deficient taste and smell.” PubMed

15. Psychosocial impact: appearance differences and delayed puberty can affect self-image and social development; support is important. (Clinical common-sense addition; aligns with case reports noting life-course impact.) PubMed

Diagnostic tests

A) Physical examination

1. Newborn airway and breathing check: immediate assessment of breathing effort, color, and chest movement to decide if airway help (oral airway, intubation) is needed. PMC

2. Craniofacial inspection and palpation: careful look and feel of the nose area, midface, and palate to document arhinia, hypoplasia, and palatal shape. PMC

3. Eye exam (external): note eye size, lid fissures, and signs suggesting microphthalmia. PMC

4. Genital exam: in males, check for descended testes; in both sexes, look for signs of puberty later in life. PubMed

5. Smell screening at appropriate age: ask about smell perception; formal smell tests come later. PubMed

B) Manual or bedside tests

6. Airflow mirror (fogging) test: hold a small mirror under the nostril area to see if condensation forms; in arhinia there is no nasal airflow. (Bedside method used in airway assessment.) PMC

7. Occlusion breathing trial (supervised): gently closing the mouth in a monitored setting highlights inability to breathe nasally; this underscores airway risk in neonates. PMC

8. Light transillumination: in older infants, shining light may show absent/narrow nasal cavities; limited but can guide imaging urgency. PMC

9. Basic smell identification cards (child-friendly): simple scents (e.g., coffee) to document anosmia or hyposmia. PubMed

10. Feeding observation: watch a feed to note fatigue, choking, or cyanosis that suggests airway compromise. PMC

C) Laboratory and pathological tests

11. Genetic testing of SMCHD1: sequencing and deletion/duplication analysis to find a pathogenic variant; many BAMS variants are missense and cluster in early exons. PubMed+1

12. Trio testing (child + both parents): clarifies if the variant is de novo or inherited; helps with recurrence risk counseling. National Organization for Rare Disorders

13. Puberty hormone panel: LH, FSH, estradiol (females), testosterone (males), ± GnRH stimulation test if needed—to confirm hypogonadotropic hypogonadism. PubMed

14. Pituitary axis screening: check prolactin, TSH/free T4, ACTH/cortisol if symptoms suggest broader pituitary involvement (rare but reasonable in syndromic hypogonadism). PubMed

15. Vision function tests: age-appropriate acuity and field tests to document impact of microphthalmia/coloboma and guide supports. PMC

D) Electrodiagnostic tests

16. Electro-olfactogram / olfactory event-related potentials (specialized centers): objective measures of smell pathway activity when behavioral testing is hard. (Used in smell disorders; applied selectively in syndromic anosmia.) PubMed

17. Visual electrophysiology (ERG/VEP): helps assess retinal/optic pathway function in microphthalmia or coloboma. (Standard in ocular malformations.) PMC

E) Imaging tests

18. Craniofacial CT (thin-cut): maps nasal bones, cavities, and choanae; essential for surgical planning and airway strategy. PMC

19. Brain and orbit MRI: evaluates olfactory bulbs/tracts, pituitary/hypothalamus, and eye/orbital structures; often shows tiny or absent olfactory bulbs. PubMed

20. 3-D CT reconstruction: provides a surgical roadmap for staged nasal reconstruction. PMC

21. Orbital ultrasound (infancy): quick, no-radiation way to estimate eye size and internal structure when MRI must wait. PMC

22. Pituitary MRI (focused): if hormones suggest central hypogonadism, this checks the pituitary anatomy. PubMed

23. Chest/airway imaging if indicated: rules out other airway anomalies that could worsen breathing. PMC

24. Dental/craniofacial radiographs later: follow jaw, palate, and dental development for orthodontic planning. PubMed

25. Prenatal ultrasound/MRI (future pregnancies): where there is a known familial variant (rare), targeted fetal imaging might detect severe nasal/ocular anomalies. (Genetic counseling practice point.) National Organization for Rare Disorders

Non-pharmacological treatments (therapies & others)

(Each lists purpose and mechanism in simple words.)

1. Neonatal airway positioning and oral airway — In the first days of life, keeping the mouth open (oral airway, McGovern nipple) helps newborns breathe until a stable plan is set. Purpose: prevent dangerous oxygen dips. Mechanism: bypasses blocked/absent nasal route so air reaches the lungs by mouth. orphananesthesia.eu+1

2. Tracheostomy (when needed acutely) — A neck breathing tube may be needed if mouth airway or intubation is not enough. Purpose: secure life-saving airflow. Mechanism: creates a direct path into the windpipe. PubMed+1

3. Early feeding support — Lactation, occupational therapy, and orogastric tube feeding reduce aspiration and malnutrition. Purpose: safe nutrition. Mechanism: adapts feeding route/positioning while nasal airway is absent. Child and Adolescent Health Service

4. Humidification and gentle suctioning — Moist air and careful oral suction keep secretions thin. Purpose: reduce blockages and infection risk. Mechanism: prevents crusting and helps mucus clear. Child and Adolescent Health Service

5. Low-vision rehabilitation — Low-vision services teach practical strategies, magnifiers, lighting, and orientation/mobility. Purpose: maximize usable vision and independence. Mechanism: compensatory training and assistive devices. PMC+1

6. Conformer therapy & ocular prosthetics — Clear conformers or prostheses expand the socket and improve facial growth when eyes are very small or absent. Purpose: support appearance, eyelid shape, and orbital growth. Mechanism: gentle, progressive socket expansion. Nature

7. Educational accommodations — Large-print materials, seating, and extra time at school. Purpose: optimize learning. Mechanism: reduces visual-task load to match ability. PMC

8. Speech-language therapy — Helps articulation and resonance in children with nasal differences. Purpose: clearer speech. Mechanism: trains breath support, oral resonance, and articulation strategies. (General SLT principles apply.)

9. Psychological support and family counseling — Addresses body image, anxiety, and social stress. Purpose: mental health and resilience. Mechanism: cognitive-behavioral tools and social skills training. (Standard psychosocial care.)

10. Sleep-disordered breathing assessment (polysomnography) & CPAP when indicated — Screens for obstructive sleep apnea in craniofacial differences; CPAP can support nighttime breathing. Purpose: quality sleep and oxygen. Mechanism: positive pressure keeps airway open. (OSA management standards; applied case-by-case in craniofacial anomalies.)

11. Nasal reconstruction planning (staged) — Timing is individualized; often delayed until facial growth allows durable results. Purpose: create nasal projection and airway. Mechanism: bone/cartilage grafts or custom implants; 3D planning is increasingly used. Lippincott Journals+1

12. Endoscopic creation/opening of posterior airway when choanal atresia co-exists — Some BAMS patients have posterior blockage. Purpose: restore nasal patency. Mechanism: endoscopic opening with stenting when needed. Children’s Hospital of Philadelphia

13. ENT care for ear ventilation and infections — Eustachian tube dysfunction can co-exist in craniofacial differences. Purpose: protect hearing. Mechanism: monitoring, tubes if indicated. (ENT standards.)

14. Orthodontic and dental care — Plan for bite, spacing, and oral hygiene issues. Purpose: healthy chewing and speech. Mechanism: braces, appliances, hygiene training. (Dental/craniofacial standards.)

15. Physical activity & bone health plan — Exercise programs help bone strength, especially with delayed sex hormones. Purpose: reduce osteoporosis risk. Mechanism: weight-bearing exercise improves bone density; pairs with endocrine care. (Endocrine bone-health principles.)

16. Fertility counseling (adolescence/young adult) — Early counseling about options reduces stress later. Purpose: future family planning. Mechanism: aligns expectations with endocrine therapies (see drug section). Oxford Academic

17. Genetic counseling — Explains SMCHD1 findings, recurrence risk, and prenatal options. Purpose: informed family planning. Mechanism: review inheritance, penetrance, and testing. PubMed

18. Sun and scar care after facial surgery — Silicone gel, sun protection, and scar massage. Purpose: better healing and cosmesis. Mechanism: reduces hypertrophic scarring. (Surgical aftercare standards.)

19. Assistive technology — Screen readers, text-to-speech, and high-contrast settings. Purpose: access school/work tasks. Mechanism: digital accessibility tools. (Low-vision rehab standards.) PMC

20. Community and peer-support linkage — Rare-disease networks improve coping and resource navigation. Purpose: social support. Mechanism: shared experience and practical tips. (Rare-disease care principles.)

---

Drug treatments

(Medication plans must be personalized by specialists; below are common, evidence-based options used to manage the hypogonadotropic hypogonadism and related issues that often accompany BAMS, plus eye-care and peri-operative needs.)

1. Testosterone (boys/men) — Class: androgen. Use: induce and maintain puberty, muscle mass, energy, bone health. Dosing/time: low dose to start, then step-up (e.g., IM testosterone or transdermal per guideline); long-term maintenance individualized. Mechanism: replaces missing testosterone. Side effects: acne, erythrocytosis, mood change; monitor labs and growth. Endocrine Society

2. Estrogen (girls/women) — Class: estrogen. Use: induce breast and uterine development, menses; bone health. Dosing/time: start low and escalate; later add progesterone for endometrial protection once breakthrough bleeding or sufficient estrogenization occurs. Mechanism: replaces missing estrogen. Side effects: breast tenderness, nausea, VTE risk (depends on route/dose). PMC

3. Progesterone (cyclic, girls/women) — Class: progestin. Use: protect uterine lining and regulate bleeding after estrogen priming. Mechanism: opposes estrogen on endometrium. Side effects: mood changes, bloating. PMC

4. Human chorionic gonadotropin (hCG, males for fertility) — Class: gonadotropin. Use: stimulate Leydig cells to produce testosterone; with/without FSH to induce spermatogenesis. Dosing/time: injections several times weekly; months. Side effects: gynecomastia, acne; monitoring required. PMC+1

5. Follicle-stimulating hormone (FSH, males for fertility) — Class: gonadotropin (hMG/FSH). Use: with hCG to start/maintain sperm production. Mechanism: acts on Sertoli cells. Side effects: injection site reactions; requires long courses. PMC+1

6. Pulsatile GnRH (males or females seeking fertility) — Class: hypothalamic hormone via pump. Use: restores physiologic signaling to pituitary to trigger LH/FSH. Dosing/time: micro-doses every 60–120 minutes via pump for weeks–months. Side effects: pump burden, local irritation. Oxford Academic+1

7. Calcium + Vitamin D (as medication-grade supplements when deficient) — Class: bone-health agents. Use: protect bone in hypogonadism or limited mobility. Mechanism: supports mineralization. Side effects: constipation; avoid excess. (Pair with endocrine care.) Medscape

8. Bisphosphonates (selected adolescents/adults with low bone density) — Class: anti-resorptives. Use: secondary osteoporosis after specialist evaluation. Mechanism: slows bone breakdown. Side effects: GI upset, rare jaw/atypical fracture risks; specialist decision only. Medscape

9. Lubricating eye drops/ointments — Class: ocular surface therapy. Use: dryness, exposure, prosthetic comfort. Mechanism: improves tear film. Side effects: transient blur/irritation. (Standard ophthalmic care.) PubMed

10. Prophylactic/therapeutic ophthalmic antibiotics (peri-procedural or infection) — Class: antimicrobial. Use: prevent/treat conjunctival or socket infection around prosthetics/surgery. Mechanism: kill bacteria. Side effects: local irritation; resistance risk—short courses only when indicated. (Ophthalmic practice standards.)

11. Analgesics (acetaminophen/ibuprofen per age/weight) — Class: pain relievers. Use: post-surgical discomfort. Mechanism: COX inhibition (NSAIDs) or central antipyretic (acetaminophen). Side effects: GI upset with NSAIDs; dose limits to protect liver/kidneys. (Pediatric surgical care norms.)

12. Nasal saline/gel for reconstructed passages (when present post-op) — Class: topical care. Use: keep new passages moist. Mechanism: hydrates mucosa, eases crust removal. Side effects: minor irritation. (ENT aftercare norms.) Children’s Hospital of Philadelphia

13. Antireflux therapy (when reflux worsens airway symptoms) — Class: acid suppression. Use: comfort and wound protection per ENT judgment. Mechanism: reduces acid exposure. Side effects: vary by agent; use only if clinically indicated. (ENT peri-airway standards.)

14. Topical silicone gel/sheets for scars — Class: topical device/medication. Use: reduce hypertrophic scarring after facial surgery. Mechanism: occlusion/hydration modulates collagen. Side effects: skin irritation. (Surgical scar-care standards.)

15. Intranasal steroids (only if a reconstructed nasal cavity with mucosa exists and is inflamed) — Class: corticosteroid spray. Use: reduce mucosal swelling post-reconstruction. Mechanism: anti-inflammatory. Side effects: epistaxis/irritation. (ENT discretion.) Children’s Hospital of Philadelphia

16. Antibiotic prophylaxis per surgical protocols (ENT/craniofacial) — Class: systemic antibiotics. Use: reduce infection risk in graft/implant surgery. Mechanism: peri-operative coverage. Side effects: allergy, GI upset; narrow spectrum per protocol. (Surgical standards.)

17. Hormonal contraception or cyclic progestin (adolescents with estrogen therapy) — Class: combined or progestin-only. Use: regulate cycles and protect endometrium during induction. Mechanism: stable endometrial shedding. Side effects: VTE risk depends on formulation/route; individualized. PMC

18. Transdermal estrogen (girls/women) and transdermal testosterone (boys/men) — Class: hormone patches/gels. Use: smoother hormone levels; sometimes lower VTE risk with transdermal estrogen. Mechanism: steady absorption. Side effects: skin irritation; careful handling. Jomh

19. Gonadotropins for female fertility (FSH/LH or hMG ± hCG trigger) — Class: fertility meds. Use: ovulation induction in women with HH. Mechanism: stimulates follicles and ovulation. Side effects: multiple gestation risk, OHSS; specialist care only. Oxford Academic

20. Bone-active agents as needed (teriparatide or others in adult cases under specialist care) — Class: anabolic/anti-resorptives. Use: selected severe osteoporosis not controlled by sex steroid replacement/lifestyle. Mechanism: stimulates bone formation or reduces resorption. Side effects: agent-specific; specialist-only decisions. Medscape

Medication caution: There is no drug that “cures” BAMS or grows a normal nose or eyes. Medicines manage consequences (breathing, eye surface, puberty, fertility, and bone). Therapy must be individualized by specialists.

---

Dietary molecular supplements

(Use only if deficient/appropriate; supplements do not repair absent nasal/ocular structures.)

1. Vitamin D3 — Dose: per labs (often 600–1000 IU/day in children; adults individualized). Function: bone mineralization with calcium. Mechanism: improves calcium absorption; counters bone risks from delayed sex hormones. (Follow local guidelines.) Medscape

2. Calcium — Dose: age-appropriate dietary goals; supplement only if diet insufficient. Function: bone strength. Mechanism: provides mineral substrate for bone. (Pair with exercise and hormones.) Medscape

3. Omega-3 (fish oil) — Dose: per product; discuss bleeding risk. Function: general cardiometabolic support; sometimes helps dry eye symptoms. Mechanism: anti-inflammatory lipid mediators. (General ophthalmic comfort evidence.)

4. Lutein/zeaxanthin — Dose: from diet (leafy greens) or supplements; data mainly in macular health. Function: retinal antioxidant support. Mechanism: filters blue light, quenches oxidative stress. (Not BAMS-specific.)

5. Balanced multivitamin (age-appropriate) — Dose: once daily standard. Function: closes dietary gaps during recovery periods. Mechanism: supportive micronutrients. (General nutrition.)

6. Protein-adequate diet — Dose: dietitian-guided grams/kg/day. Function: wound healing after surgeries and growth. Mechanism: supplies amino acids for tissue repair. (Surgical nutrition principles.)

7. Iron (only if iron deficiency is proven) — Dose: per ferritin/TSAT and age. Function: correct anemia that worsens fatigue. Mechanism: restores hemoglobin. (Treat deficiency only.)

8. Zinc (short-term post-op if deficient) — Dose: as per labs/dietitian. Function: wound healing. Mechanism: supports collagen and immune enzymes. (Wound-healing nutrition.)

9. Vitamin A caution — Note: high-dose vitamin A in pregnancy is teratogenic; in children, avoid unnecessary high doses. Function/Mechanism: fat-soluble vitamin; use only under medical advice. (Teratogen counseling applies.)

10. Hydration & fiber plan — Dose: age-appropriate fluids/fiber grams. Function: prevent constipation while on pain meds. Mechanism: improves GI motility. (Post-op care.)

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved immune-booster, regenerative, or stem-cell drugs for BAMS. Claims to “regrow” nasal or eye structures with pills or injections are not evidence-based and may be unsafe. Research and reconstructions are surgical/engineering (e.g., grafts, custom implants, 3-D planning), not drug-based. If you see such offers, seek a second opinion from a university-affiliated craniofacial center. PMC

---

Surgeries

1. Emergency airway (tracheostomy or surgical creation of airway) — Why: life-saving breathing access in severe neonatal obstruction. Procedure: neck tube or creation of a nasal passage if feasible. PMC

2. Endoscopic repair of choanal atresia (if present) — Why: open the back of the nose to allow airflow. Procedure: endoscopic opening with careful stenting and follow-up. Children’s Hospital of Philadelphia

3. Staged nasal reconstruction — Why: provide nasal projection and, when possible, a functional airway; also cosmetic and psychosocial benefits. Procedure: cartilage/bone grafts or custom alloplastic implants with 3-D planning; usually staged over time. Lippincott Journals+1

4. Orbital/eyelid procedures with conformers or implants — Why: expand the socket, improve eyelid closure, comfort with prosthesis. Procedure: gradual conformer sizing; prosthetic eye fitting; eyelid repairs if needed. Nature

5. Adjunct craniofacial/dental/orthognathic surgeries — Why: optimize function (speech, bite, airway) and appearance as the child grows. Procedure: individualized by a craniofacial board (ENT, plastics, OMFS, orthodontics). (Craniofacial standards of care.)

---

Prevention tips

1. Genetic counseling pre-pregnancy to discuss SMCHD1 findings and recurrence risk. (Helps informed choices.) PubMed

2. Early high-risk pregnancy care if there is a family history or known variant (targeted ultrasound/MRI per specialist).

3. Avoid known teratogens (e.g., isotretinoin/vitamin A excess, alcohol, tobacco, non-prescribed drugs).

4. Vaccinations and infection prevention in pregnancy (per national schedules) — reduces congenital infection risks.

5. Folic acid before and during early pregnancy for general neural/craniofacial risk reduction.

6. Medication review pre-conception with obstetric and genetics teams.

7. Healthy maternal diet and diabetes control to reduce general malformation risks.

8. Environmental safety (avoid toxic exposures at work/home).

9. Newborn readiness plan (deliver where NICU/airway/ENT teams are available if arhinia is suspected on prenatal imaging). PMC

10. Lifelong accident prevention for low vision (home lighting, contrast strips, mobility training). PMC

---

When to see a doctor (red flags)

• Newborn period: any trouble breathing, feeding, blue spells, or poor weight gain — emergency assessment now. PMC

• Any age: noisy sleep, pauses in breathing, daytime sleepiness → sleep study.

• Eye symptoms: pain, discharge, sudden vision changes, prosthesis discomfort → urgent ophthalmology. PubMed

• Puberty delay: no signs of puberty by expected ages (girls ~13, boys ~14) or stalled progression → endocrine evaluation for HH. PMC

• Post-surgery: fever, increasing redness, pus, severe pain, or bleeding → surgical team now.

---

“What to eat” and “what to avoid” (simple guidance)

• Eat: balanced meals with lean protein, fruits/vegetables, whole grains, and dairy/fortified alternatives for calcium and vitamin D; aim for adequate calories and protein during growth and after surgery. Why: supports healing, bone health, and energy. Medscape

• If a dietitian advises: add supplements (vitamin D, calcium, iron) only when lab-proven or clinically indicated.

• Hydrate well and include fiber to prevent constipation during pain-medication periods.

• Avoid: high-dose “immune boosters,” megavitamins (especially vitamin A), unregulated herbal products, and crash diets. Why: no benefit for BAMS structures; potential harm and interactions.

• All ages: keep safe swallowing and reflux control in mind after airway procedures; follow individualized feeding plans.

---

Frequently asked questions (FAQs)

1) Is BAMS curable with medicines?
No. Medicines cannot regrow a nose or fully develop eyes. Treatment focuses on airway safety, eye protection/rehab, and hormone replacement for puberty and fertility. MedlinePlus

2) What causes BAMS?
Most known cases are linked to variants in SMCHD1, a gene involved in early development. Not all cases have a detectable change, but SMCHD1 is the strongest signal so far. PubMed+1

3) How rare is it?
Only about a hundred cases have been described worldwide. PubMed+1

4) Why is the newborn period risky?
Newborns prefer to breathe through the nose. Without a nose/nasal passage, they may not get enough air during feeding or sleep and can need urgent airway support. PMC

5) Can surgery build a nose and airway?
Reconstruction is possible, often in stages, sometimes with 3-D planning and custom implants. Timing is individualized. Lippincott Journals+1

6) Will my child be able to smell or taste?
Hyposmia or anosmia is common because the olfactory system may be under-developed. Some may have partial function, but many have little or none. (Feature descriptions.) Orpha

7) What about vision?
Microphthalmia/anophthalmia ranges from mild to severe. Low-vision rehab, conformers, and prosthetics can help function and appearance. PubMed+1

8) How is puberty managed?
Endocrinology teams use stepwise estrogen+progesterone (girls) or testosterone (boys) to induce puberty safely and protect bones. PMC+1

9) Can people with BAMS have children?
Many can, with help. Pulsatile GnRH or gonadotropin therapy (hCG/FSH) often restores spermatogenesis or ovulation. Oxford Academic+1

10) Is gene therapy available?
No. Current care is supportive and surgical; research continues in craniofacial development. PubMed

11) What specialists should be on the team?
Neonatology/NICU, ENT/airway, craniofacial/plastic surgery, ophthalmology & low-vision, endocrinology, speech-language, dentistry/orthodontics, psychology, genetics.

12) Are there risks from hormone therapy?
Yes, like acne, mood changes, blood counts (boys), and VTE risk (estrogen depends on route). Benefits usually outweigh risks when monitored by specialists. Endocrine Society+1

13) How often are checkups needed?
Regular follow-up is essential: growth/puberty checks, bone health, vision/prosthesis care, airway and sleep assessment, and surgical follow-up. Medscape

14) What home changes help low vision?
Brighter lighting, high-contrast tape on steps/edges, decluttering, and using magnifiers or screen readers. PMC

15) Where can families find support?
Rare-disease groups and low-vision services provide training, devices, and community connections. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 22, 2025.